Quantcast
Last updated on April 16, 2014 at 7:25 EDT

Latest Biomedical Advanced Research and Development Authority Stories

2014-01-09 08:27:11

Presentation to be Webcast Live on January 14, 2014 at 11AM PST PRINCETON, N.J., Jan. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD,...

2014-01-06 08:25:32

PRINCETON, N.J., Jan. 6, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified...

2013-11-21 08:27:05

PRINCETON, N.J., Nov. 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC) providing an initial investment in Soligenix of $600,000 and...

2013-11-15 08:27:52

Order completion results from a successful collaboration between Bavarian Nordic and the U.S. government that has continued for more than a decade KVISTGAARD, Denmark, November 15, 2013 /PRNewswire/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that it completed the delivery of 20 million doses of IMVAMUNE(R) smallpox vaccine to the U.S. Strategic National Stockpile (SNS) for use in the event of a smallpox emergency in the U.S. This order completion is the result of...

2013-11-12 23:20:13

Countervail’s advanced development contract with BARDA fully realized is valued at $24.9 million over a five year period. Sarin, Soman, VX, Tabun, and Cyclosarin are examples of extremely toxic organophosphorus based compounds created for use as chemical weapons. Charlotte, NC (PRWEB) November 12, 2013 CHARLOTTE, NC, Nov 8, 2013 /PRWeb/ -- Countervail Corporation announced today the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development...

2013-11-12 08:34:31

PRINCETON, N.J., Nov. 12, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the quarter and nine months ended September 30, 2013. Soligenix's revenues for the quarter and nine months ended were $0.3...

2013-10-31 23:04:45

Texas A&M Health Science Center (TAMHSC) is continuing to lead national public health preparedness initiatives with the appointment of Gerald Parker, Jr., D.V.M., Ph.D., M.S., as the TAMHSC vice president for public health preparedness and response. College Station, Texas (PRWEB) October 31, 2013 Prior to accepting the position, Parker served as a deputy assistant secretary of defense where he was responsible for developing national strategies to protect United States service members...

2013-10-28 16:20:17

Work Supports Government Project with Argentum Medical. KANSAS CITY, Mo., Oct. 28, 2013 /PRNewswire-USNewswire/ -- MRIGlobal today announced that it will work with Argentum Medical LLC, which was awarded a $7.8 million, 24-month contract by the Department of Health and Human Services, Biomedical Advanced Research and Development Authority. (Logo: http://photos.prnewswire.com/prnh/20130730/DC55501LOGO-a) MRIGlobal will support Argentum Medical by developing comprehensive treatment...

2013-10-22 08:31:56

GENEVA, Ill., Oct. 22, 2013 /PRNewswire/ -- Argentum Medical, an industry leading manufacturer of metallic silver based antimicrobial wound dressings, announced today that it has been awarded a contract by Biomedical Advanced Research and Development Authority (BARDA). Under this contract, Argentum Medical will conduct studies to evaluate the use of its Silverlon® brand burn and wound trauma dressings for potential use on patients affected by mass casualty incidents involving...

2013-10-21 08:28:41

PRINCETON, N.J., Oct. 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today the appointment of Marco Maria Brughera, DVM, Global Head of the Rare Disease Franchise for Sigma-Tau SpA, to its Board of Directors. "We are pleased to welcome Dr. Brughera to...